A biosimilar of infliximab, CT-P13, has equivalent safety and efficacy to that of the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn's disease in infliximab-naïve patients. Findings from a comparative equivalence cohort study are published in Annals of Internal Medicine.
from Medical Xpress - latest medical and health news stories https://ift.tt/2C2v78f
via IFTTT
No comments:
Post a Comment